Last reviewed · How we verify
NCT07210125: L4PinPharm
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
Phase 4 trial testing Lenacapavir long-acting in HIV in 75 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2027
Quick facts
| Lead sponsor | Kelley-Ross & Associates, Inc. |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 75 |
| Start date | 16 September 2025 |
| Primary completion | 31 March 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Lenacapavir long-acting — full drug profile →
- Standard of Care (SOC) — full drug profile →
Conditions studied
- HIV — all drugs for HIV →
Sponsor
Kelley-Ross & Associates, Inc.
Who can join
18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07210125
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lenacapavir long-acting
Trials testing the same drug.
- NCT07218211 — Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP · Phase 4 · recruiting
- NCT06970223 — A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable W · Phase 1 · active not recruiting
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other Kelley-Ross & Associates, Inc. trials
Trials by the same sponsor.
- NCT05867212 — Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07210125 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kelley-Ross & Associates, Inc.
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07210125.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing